Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Status:
Completed
Trial end date:
2018-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of a new critical pathway (use of
guideline-based patient identification criteria and for those who meet these criteria, use of
dalbavancin) compared to usual care for the treatment of ABSSI (Acute Bacterial Skin and Skin
Structure Infections)